Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
AMGN is in the long-term up 382% in 16 years.
Description: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company?s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate
|Shares Outstanding||EPS||10.63||EPS Growth - 4 Quarters||-5.54%||EPS Growth - Q/Q||23.37%|
|EPS Growth - Y/Y||-9.79%||Sales Growth - 4 Quarters||-2.84%||Sales Growth - Q/Q||-5.59%||P/E||15.28|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||8.28%||ROE||21.53%||ROI||9.63%|
|Current Ratio||5.53||Quick Ratio||5.11||Long Term Debt/Equity||1.04||Debt Ratio||0.24|
|Gross Margin||78.78%||Operating Margin||33.29%||Net Profit Margin||27.74%||Dividend Payout Ratio||-34.86%|
|Cash From Financing Activities||-1.24 B||Cash From Investing Activities||-952 M||Cash From Operating Activities||1.33 B||Gross Profit||4.57 B|
|Net Profit||1.65 B||Operating Profit||2.08 B||Total Assets||71.21 B||Total Current Assets||37.74 B|
|Total Current Liabilities||6.89 B||Total Debt||31.95 B||Total Liabilities||43.73 B||Total Revenue||5.37 B|
|High 52 week||206.65||Low 52 week||165||Last close||194.87||Last change||5.95%|
|RSI||76.37||Average true range||5.08||Beta||0.85||Volume||2.05 M|
|Simple moving average 20 days||8.76%||Simple moving average 50 days||8.94%||Simple moving average 200 days||5.51%|
|Performance Week||4.82%||Performance Month||10.25%||Performance Quart||15.18%||Performance Half||5.58%|
|Performance Year||0.68%||Performance Year-to-date||0.88%||Volatility daily||2%||Volatility weekly||4.47%|
|Volatility monthly||9.16%||Volatility yearly||31.75%||Relative Volume||183.77%||Average Volume||2.88 M|
|New High||New Low|
2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?
2019-10-18 09:00:00 | Nplate® romiplostim Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
2019-10-18 07:04:11 | Alexion to Buy Achillion for $930M, Strengthen PNH Franchise
2019-10-17 11:16:03 | Roche Posts Solid Sales for First 9 Months of '19, Ups View
2019-10-17 10:54:02 | Can New Drugs Help Lilly LLY to Deliver Solid Q3 Earnings?
2019-10-16 11:43:56 | Alexion makes $930M acquisition in bid to bolster blockbuster drug
2019-10-16 09:17:01 | Biogen BIIB to Report Q3 Earnings: What's in the Cards?
2019-10-15 17:45:09 | Amgen AMGN Gains But Lags Market: What You Should Know
2019-10-15 14:39:49 | Sanofi opens new Framingham site amid $1.6B bet on bio-manufacturing
2019-10-15 09:00:00 | Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team
2019-10-14 10:14:02 | Lilly Gets FDA Approval for New Oral Tablets for Migraine
2019-10-14 09:28:01 | Roche Announces Positive Late-Stage Data on Rituxan in PV
2019-10-11 16:27:22 | Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off
2019-10-11 12:29:04 | Top Research Reports for Toyota, Amgen & TJX
2019-10-11 09:27:01 | Alexion ALXN Collaborates With Stealth BioTherapeutics
2019-10-10 10:58:02 | 3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
2019-10-10 07:03:26 | Should You Be Worried About Insider Transactions At Amgen Inc. NASDAQ:AMGN?
2019-10-09 17:45:09 | Amgen AMGN Gains But Lags Market: What You Should Know
2019-10-09 16:46:03 | Is Amgen, Inc. AMGN A Good Stock To Buy According To Hedge Funds?
2019-10-09 09:04:00 | Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
2019-10-08 15:10:35 | Phillips 66 puts former Walmart CFO on board
2019-10-08 11:43:35 | UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report
2019-10-08 09:18:01 | Why Alexion is a Hot Takeover Target in the Biotech Sector
2019-10-07 10:36:27 | Pfenex Gets FDA Seal of Approval For Amgen's Forteo Biosimilar
2019-10-07 09:30:01 | Has Amgen AMGN Outpaced Other Medical Stocks This Year?
2019-10-07 06:00:00 | After 500% Surge, Mirati’s Day of Reckoning Is Approaching
2019-10-04 16:29:42 | A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering
2019-10-04 09:30:57 | 3 Drug Stocks Poised for Gains After Cancer Conference
2019-10-03 17:45:09 | Amgen AMGN Outpaces Stock Market Gains: What You Should Know
2019-10-03 15:49:50 | Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar
2019-10-03 11:22:03 | Merck's Pediatric Filings for Dificid Get FDA's Priority Review
2019-10-03 07:00:00 | Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona
2019-10-02 11:04:56 | Seeing the Baseline
2019-10-02 07:34:11 | Top Ranked Income Stocks to Buy for October 2nd
2019-10-01 09:10:01 | Should Value Investors Buy Amgen AMGN Stock?
2019-09-30 14:07:00 | Seattle Genetics, Merck, Bristol-Myers Unveil Upbeat Treatment Data at Cancer Conference
2019-09-28 10:59:17 | UPDATE 1-Targeted Amgen drug has low response rate in colon cancer in study
2019-09-28 01:30:00 | Low response rate reported for Amgen targeted drug in colon cancer trial
2019-09-27 21:52:00 | Bye-bye, Biotech Funds? Not So Fast. It Could Be Time for Another Look
2019-09-27 17:50:09 | Amgen AMGN Stock Moves -0.23%: What You Should Know
2019-09-27 09:34:01 | Should First Trust Capital Strength ETF FTCS Be on Your Investing Radar?
2019-09-26 16:55:08 | Cutting Rates 50 bps. Smart, Dumb, Not Enough?
2019-09-26 12:05:04 | Medicines Company's Inclisiran Succeeds in Pivotal Studies
2019-09-26 09:02:01 | Incyte Treats First Patient in Phase III Vitiligo Study